Aurobindo Pharma Subsidiary Receives Fda Nod For Hypogonadism Treatment

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Aurobindo Pharma subsidiary receives FDA nod for Hypogonadism treatment

ri-calendar-2-lineOct 23, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Aurobindo Pharma announced on October 23 that its wholly owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to produce and market a drug for the treatment of hypogonadism.

 

The approved drug is Testosterone Cypionate Injection USP, available in strengths of 1,000 mg/10 mL (100 mg/mL) and 2,000 mg/10 mL (200 mg/mL) in Multi-Dose Vial, as well as 200 mg/mL in Single-Dose Vial. This formulation is deemed bioequivalent and therapeutically equivalent to Pfizer Inc.'s reference listed drug (RLD), Depo-Testosterone Injection, available in 100 mg/mL and 200 mg/mL.

 

Testosterone Cypionate Injection USP is prescribed for replacement therapy in males experiencing conditions linked to symptoms of deficient or absent endogenous testosterone, including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

 

The product is slated for launch in November 2023, and it holds an estimated market size of US$ 226.8 million for the twelve months leading up to August 2023, according to IQVIA.

 

Aurobindo Pharma notes that this approval marks the 169th ANDA approval (including 9 tentative approvals) from Eugia Pharma Speciality Group (EPSG) facilities, which manufacture both oral and sterile specialty products.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions